ANKTIVA

(Anktiva)

Phase 2Small molecule

AAltor BioScience

ANKTIVA is one of 3 small molecule programs targeting Long COVID. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Long COVIDRecruiting

Long COVIDPhase 2

Recruiting

Competition

Competitive Landscape

2 competitors in Long COVID

#DrugCompanyPhaseTrials

Olumiant

Eli Lilly

Phase 3

1 2

ANKTIVA

AAltor BioScience

Phase 2

1 3

Taurine

TThird Military Medical University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Long COVID

NCT07123727

Clinical

Trials by Indication[1]

Long COVID1 trial

Single Arm Study to Evaluate the Safety of Nogapendekin Alfa Inbakicept (NAI) in Participants With Long COVID

Recruiting·IImmunityBio, Inc.·Phase 2·NCT07123727·40 enrolled

Regulatory

FDA Approval Timeline[4]

Apr 22, 2024

ANKTIVA

BLA BLA761336

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Anktiva. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anktiva compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anktiva. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA761336). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Altor BioScience company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAltor BioScience

ANKTIVA

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Long COVID1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News